Literature DB >> 7857413

[Association of Castleman's disease and Hodgkin's disease. Eight cases and review of the literature].

V Molinié1, G Périé, I Mélo, C Melo, J Audouin, J Diebold.   

Abstract

We have recorded 8 patients presenting a Hodgkin's disease associated with Castleman's disease. Four men and 4 women with a 44 years mean age (15-60), presented as a solitary mass (2/7) or as a multicentric tumoral disease (5/7). One of our patients was HIV. Histological studies showed typical features of Castleman's disease. Nodular sclerosing Hodgkin's disease with numerous lacunar cells were present in 3 cases, interfollicular Hodgkin's disease in 4 cases and nodular paragranuloma in one case. Hodgkins' and Reed Sternberg cells were positive for CD15 (4/7), CD30 (5/7), EMA (3/6) and LMP-1 (4/5). In situ hybridization on tissue sections demonstrate presence of EBV DNA in one case and EBER1-RNA in 2 of 4 cases. The difficulty in making the diagnosis of Hodgkin's disease the relation between both diseases, and the role of IL-6 are discussed.

Entities:  

Mesh:

Year:  1994        PMID: 7857413

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  2 in total

1.  International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

Authors:  Frits van Rhee; Eric Oksenhendler; Gordan Srkalovic; Peter Voorhees; Megan Lim; Angela Dispenzieri; Makoto Ide; Sophia Parente; Stephen Schey; Matthew Streetly; Raymond Wong; David Wu; Ivan Maillard; Joshua Brandstadter; Nikhil Munshi; Wilbur Bowne; Kojo S Elenitoba-Johnson; Alexander Fössa; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Sheila K Pierson; Amy Greenway; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Amy Chadburn; David C Fajgenbaum
Journal:  Blood Adv       Date:  2020-12-08

2.  Acute myelogenous leukemia M5b developed during clinical remission of Castleman disease.

Authors:  Akira Tomonari; Naoki Shirafuji; Arinobu Tojo; Tohru Iseki; Jun Ooi; Itaru Komiya; Kenzaburo Tani; Shigetaka Asano
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.319

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.